Insights - Yet another choppy week for investors, and we’re going into another weekend in which decisions overseas will impact U.S. markets first thing on Monday. Greece submitted … Continue Reading
Read nowInsights - Just in front of its option deadline, Celgene (CELG) has re-upped on an existing research and discovery collaboration with Epizyme (EPZM), a developer of targeted cancer … Continue Reading
Read nowzPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
PremiumInsights - Celgene (CELG) has placed its bet in the race to develop and market T cell therapies for oncology with a $1 billion infusion in cell therapy … Continue Reading
Read nowInsights - That’s a bit disingenuous, but Seres Health’s (MCRB) SER-109 isn’t far from it. The company made a splash on Friday when it IPO’d at $18, and … Continue Reading
Read nowInsights - Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies (AAVL) blew up spectacularly this Monday with … Continue Reading
Read nowRecap - If you were hiding under a rock this week, three events stood out in the world of biotech investing. On Tuesday and Wednesday, a panel … Continue Reading
Read now
